Merck delivered a strong Q4 double beat, with robust pipeline momentum and a healthy new launch cycle. Read more on the ...

For full-year 2025, Merck reported worldwide sales of $65B, up 1% Y/Y, or 2% excluding FX, while adjusted EPS totaled $8.98.

Merck will report its earnings on Tuesday, offering insights into how its agreement to lower the price of its diabetes drug ...

AZN misses Q4 EPS and sales estimates, but rallies after projecting mid-to-high single-digit revenue growth and low ...

Merck (NYSE:MRK) has received Health Canada approval for ENFLONSIA (clesrovimab), a monoclonal antibody for RSV prevention in ...

Merck & Co. reports Q4 2025 earnings on Tuesday, Feb. 3, 2026, before market open. Wall Street expects earnings of $2.01 per ...

Merck & Co., Inc. stock reached a 52-week high, closing at $112.91. This milestone reflects a significant upward trend for the pharmaceutical giant, with its stock price appreciating by 13.07% over ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the ...

Merck & Co shares are trading up 1.19% at $107.25 at the time of this writing on Thursday morning. About Merck & Co. Merck makes pharmaceutical products to treat several condition ...

It was revealed in a recent SEC filing that Chirfi Guindo, Chief Marketing Officer at Merck & Co (NYSE: MRK) made a ...

Detailed price information for Summit Therapeu ADR (SMMT-Q) from The Globe and Mail including charting and trades.

If you are wondering whether Merck’s current share price lines up with its underlying value, you are not alone, and this ...